Christian Thienel

Back Bay’s director discusses why IBD remains underserved — JAK inhibitor constraints, emerging oral mechanisms, and the durability gap.

Back Bay’s director discusses why IBD remains underserved — JAK inhibitor constraints, emerging oral mechanisms, and the durability gap.

Christian Thienel on the oral IBD mechanisms generating the most excitement — SIK2, oral IL-23, TYK2 — and why multiple could succeed.

Christian Tinel on why Rinvoq succeeds in IBD despite safety concerns — and what a cleaner oral alternative would mean for the market.

Christian Thienel on why IBD's unmet need comes down to one thing: an oral therapy with biologic-like efficacy and better safety.